Stock fact sheet · data as of
biote Corp. (BTMD): fair value, margin of safety and Wheel Score
Healthcare · Medical - Care Facilities · United States · Value
Is BTMD undervalued?
At 1.11 (close of 16 Oct 2026), BTMD trades 90% below the GLS average fair value of 11.26. That average comes from 7 models run on the latest filings, and 7 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns biote Corp. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between EPV (2.27) and Payback Time (20.25). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files BTMD under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for BTMD
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 10.36 | +833% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | 11.70 | +954% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 5.11 | +361% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 12.52 | +1028% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 16.57 | +1393% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 20.25 | +1724% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 2.27 | +105% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -2.34 | -311% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 4.00 | +260% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
biote Corp. scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 3.9/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 52.6%, ROE -46.2%, ROA 25.1% - with debt at -1.88 times equity and a free-cash-flow yield of 40.2%.
biote Corp. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product Revenue 77%, Dietary Supplements 20%, Service Revenue 2% (quarter Q2 FY2026).
Institutional ownership scores 6/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 52.6% |
|---|---|---|---|
| GLS Moat | 3.9 / 10 | ROE | -46.2% |
| Debt / equity | -1.88 | ROA | 25.1% |
| Free-cash-flow yield | 40.2% | Payout ratio | 2% |
| Institutions | 6 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
No options are listed on biote Corp. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 43k shares a day on a market cap of $49M, with a beta of 1.69 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 4 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 90% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 6 / 15 | moat 3.9/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 4 / 20 | 43k shares/day, $49M cap, beta 1.69 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 4 Nov 2026 (after the close), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Care Facilities
The 12 companies below are the closest to biote Corp. by market cap within the Medical - Care Facilities industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| EUDA EUDA Health Holdings Limited | 15.49 | - | - | 31No options | $46M |
| CCEL Cryo-Cell International, Inc. | 3.65 | 11.97 | +69% | 39No options | $29M |
| DCGO DocGo Inc. | 0.2820 | - | - | 40Weak | $28M |
| PARK Park Dental Partners, Inc. Common Stock | 19.00 | 17,706.27 | +100% | 39No options | $90M |
| JYNT The Joint Corp. | 6.91 | 4.08 | -69% | 38Weak | $98M |
| AIRS AirSculpt Technologies, Inc. | 1.42 | - | - | 36Weak | $102M |
| GBCS Selectis Health, Inc. | 5.73 | 128.82 | +96% | 39No options | $18M |
| PIII P3 Health Partners Inc. | 4.37 | - | - | 24No options | $14M |
| RHEPB Regional Health Properties, Inc. | 6.25 | 39,547.42 | +100% | 39No options | $11M |
| KJFI Comjoyful International Company | 0.9740 | - | - | 31No options | $212M |
| SYRA Syra Health Corp. Class A Common Stock | 0.8430 | 0.2255 | -274% | 14No options | $10M |
| AMS American Shared Hospital Services | 1.26 | 6.91 | +82% | 39No options | $8M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BTMD
Is BTMD undervalued right now?
By the GLS models, yes: at 1.11 the stock is 90% below the average fair value of 11.26 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of BTMD and what does it mean?
BTMD has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for BTMD?
11.26 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does biote Corp. report earnings next?
The next earnings report is due on 4 Nov 2026 (after the close), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does BTMD have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on BTMD, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.